IDEXX Laboratories Balance Sheet
NASDAQ: IDXXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEXX Laboratories financial position
At the end of fiscal 2025, IDEXX Laboratories reported total assets of $3.35 billion, up 1.7% from a year earlier against total liabilities of $1.75 billion. Shareholders' equity stood at $1.61 billion, or 47.9% of assets. The company held $180.1 million in cash and equivalents against $449.8 million of debt, a net debt position of $269.8 million.
The current ratio (current assets divided by current liabilities) was 1.23, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.28.
Summary generated from market data by MetaCap's automated system. Methodology
IDEXX Laboratories balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 180.07M | 288.27M | 453.93M | 112.55M | 144.45M | 383.93M | 90.33M | 123.79M | 187.68M | 154.90M |
| Short-Term Investments | — | — | — | — | — | — | — | 0 | 284.25M | 236.95M |
| Receivables | 552.38M | 473.57M | 457.44M | 400.62M | 368.35M | 331.43M | 269.31M | 248.85M | 234.60M | 204.49M |
| Inventory | 377.76M | 381.88M | 380.28M | 367.82M | 269.03M | 209.87M | 195.02M | 173.30M | 164.32M | 158.03M |
| Total Current Assets | 1.41B | 1.40B | 1.50B | 1.10B | 955.65M | 1.06B | 679.64M | 654.17M | 971.99M | 845.58M |
| Property, Plant & Equipment | 747.38M | 713.12M | 702.18M | 649.47M | 587.67M | 555.17M | 533.85M | 437.27M | 379.10M | 357.42M |
| Goodwill | 414.00M | 405.10M | 366.00M | 361.80M | 359.35M | 243.35M | 239.72M | 214.49M | 199.87M | 178.23M |
| Intangible Assets | 109.84M | 111.68M | 84.50M | 97.67M | 99.03M | 52.54M | 58.47M | 41.83M | 43.85M | 46.16M |
| Total Assets | 3.35B | 3.29B | 3.26B | 2.75B | 2.44B | 2.29B | 1.83B | 1.54B | 1.71B | 1.53B |
| Accounts Payable | 110.41M | 114.21M | 110.64M | 110.22M | 116.14M | 74.56M | 72.17M | 69.53M | 66.97M | 60.06M |
| Short-Term Debt | 75.00M | 167.79M | 75.00M | 74.98M | 75.00M | 49.99M | 0 | — | — | — |
| Total Current Liabilities | 1.15B | 1.07B | 951.55M | 1.24B | 763.58M | 582.76M | 725.34M | 770.44M | 1.00B | 934.57M |
| Long-Term Debt | 374.84M | 449.79M | 622.88M | 694.39M | 775.21M | 858.49M | 698.91M | 601.80M | 606.60M | 593.70M |
| Total Liabilities | 1.75B | 1.70B | 1.78B | 2.14B | 1.75B | 1.66B | 1.65B | 1.55B | 1.77B | 1.64B |
| Shareholders' Equity | 1.61B | 1.60B | 1.48B | 608.74M | 689.99M | 632.09M | 177.47M | -9.51M | -54.11M | -108.35M |
| Retained Earnings | 6.39B | 5.33B | 4.44B | 3.60B | 2.92B | 2.18B | 1.60B | 1.17B | 803.54M | 540.40M |
| Total Debt | 449.84M | 617.57M | 697.88M | 769.37M | 850.20M | 908.48M | 698.91M | 601.80M | 606.60M | 593.70M |
| Net Cash (Debt) | -269.77M | -329.31M | -243.95M | -656.82M | -705.75M | -524.55M | -608.58M | -478.01M | -134.67M | -201.85M |
| Shares Outstanding | 79.71M | 81.60M | 83.03M | 82.89M | 84.56M | 85.45M | 85.47M | 86.10M | 87.10M | — |
This table shows 10 annual periods of IDEXX Laboratories's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IDXX's reporting calendar. What is a balance sheet?